Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6905934 | 0.86 | KIF11 (0.42) | KDM4EKMT2AKIF11ALDH1A1HPGD | |
| SCHEMBL6912324 | 0.86 | KIF11 (0.42) | KDM4EKMT2AKIF11ALDH1A1HPGD | |
| SCHEMBL6912027 | 0.86 | KIF11 (0.42) | KDM4EKMT2AKIF11ALDH1A1HPGD | |
| SCHEMBL7072940 | 0.84 | KIF11 (0.35) | KDM4EKMT2AMAOAKIF11ALDH1A1 | |
| SCHEMBL7070543 | 0.84 | MTNR1A (0.50) | KDM4EMTNR1AMTNR1BKMT2AMAOA | |
| SCHEMBL7069439 | 0.81 | KDM4E (0.42) | KDM4EMTNR1AMTNR1BKMT2AMAOA | |
| SCHEMBL7070541 | 0.79 | MTNR1A (0.51) | KDM4EMTNR1AMTNR1BKMT2AMAOA | |
| SCHEMBL7113382 | 0.77 | MTNR1A (0.60) | KDM4EMTNR1AMTNR1BKMT2AMAOA | |
| SCHEMBL7106197 | 0.76 | L3MBTL1 (0.53) | KDM4EMTNR1AMTNR1BKMT2AMAOA | |
| SCHEMBL7980653 | 0.75 | MAPT (0.40) | KDM4EKMT2AALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882707-B1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | ASAHI CHEMICAL IND (JP) | 2003-10-08 | — | — | EP | disclosed |
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | disclosed |
| US-20030073644-A1 | Combinations comprising a beta-agonist and a further antidiabetic agent | SMITHKLINE BEECHAM P.L.C. | 2003-04-17 | — | — | US | disclosed |
| US-6545053-B1 | Aminoethoxyfluorene derivatives are beta-3 adrenaline receptor agonists and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc. | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-04-08 | — | — | US | disclosed |
| US-6187809-B1 | BETA-3 ADRENALINE RECEPTOR AGONIST DRUGS FOR THE TREATMENT OF DIABETES, OBESITY, AND HYPERLIPEMIA; 2-(N-(2-(DIBENZOFURAN-3-YLOXY)ETHYL)AMINO)-1-PHENYLETHANOL, FOR EXAMPLE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2001-02-13 | — | — | US | disclosed |
| US-6037362-A | CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0882707-A1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ADRB3, MC2R, NR3C1 | KDM4E 2447/4885MTNR1A 109/4885MTNR1B 150/4885 |
| US-20030073644-A1 | Combinations comprising a beta-agonist and a further antidiabetic agent | ADRB1, ADRB2, ADRB3 | KDM4E 4572/4885MTNR1A 100/4885MTNR1B 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.